 Microbial Sensitivity Tests
"Microbial Sensitivity Tests" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses).
| Descriptor ID |
D008826
|
| MeSH Number(s) |
E01.370.225.875.595 E05.200.875.595 E05.337.550.400
|
| Concept/Terms |
Microbial Sensitivity Tests- Microbial Sensitivity Tests
- Microbial Sensitivity Test
- Sensitivity Test, Microbial
- Sensitivity Tests, Microbial
- Test, Microbial Sensitivity
- Tests, Microbial Sensitivity
- Drug Sensitivity Assay, Microbial
Minimum Inhibitory Concentration- Minimum Inhibitory Concentration
- Concentration, Minimum Inhibitory
- Concentrations, Minimum Inhibitory
- Inhibitory Concentration, Minimum
- Inhibitory Concentrations, Minimum
- Minimum Inhibitory Concentrations
Bacterial Sensitivity Tests- Bacterial Sensitivity Tests
- Tests, Bacterial Sensitivity
- Sensitivity Tests, Bacterial
- Test, Bacterial Sensitivity
- Bacterial Sensitivity Test
- Sensitivity Test, Bacterial
|
Below are MeSH descriptors whose meaning is more general than "Microbial Sensitivity Tests".
Below are MeSH descriptors whose meaning is more specific than "Microbial Sensitivity Tests".
This graph shows the total number of publications written about "Microbial Sensitivity Tests" by people in this website by year, and whether "Microbial Sensitivity Tests" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 | | 1997 | 0 | 3 | 3 | | 1998 | 0 | 2 | 2 | | 1999 | 0 | 1 | 1 | | 2001 | 0 | 2 | 2 | | 2002 | 0 | 1 | 1 | | 2003 | 0 | 5 | 5 | | 2004 | 0 | 7 | 7 | | 2005 | 0 | 4 | 4 | | 2006 | 0 | 5 | 5 | | 2007 | 0 | 4 | 4 | | 2008 | 0 | 9 | 9 | | 2009 | 0 | 7 | 7 | | 2010 | 0 | 9 | 9 | | 2011 | 0 | 13 | 13 | | 2012 | 1 | 18 | 19 | | 2013 | 0 | 12 | 12 | | 2014 | 1 | 8 | 9 | | 2015 | 1 | 6 | 7 | | 2016 | 1 | 10 | 11 | | 2017 | 0 | 15 | 15 | | 2018 | 2 | 9 | 11 | | 2019 | 3 | 14 | 17 | | 2020 | 1 | 13 | 14 | | 2021 | 0 | 16 | 16 | | 2022 | 0 | 8 | 8 | | 2023 | 0 | 7 | 7 | | 2024 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Microbial Sensitivity Tests" by people in Profiles.
-
Soto CL, Hsu AJ, Lee JH, Dzintars K, Choudhury R, Jenkins TC, McCreary EK, Quartuccio KS, Stohs EJ, Zimmerman M, Tamma PD. Identifying Effective Durations of Antibiotic Therapy for the Treatment of Carbapenem-resistant Enterobacterales Bloodstream Infections: A Multicenter Observational Study. Clin Infect Dis. 2024 01 25; 78(1):27-30.
-
Yellepeddi VK, Lindley B, Radetich E, Kumar S, Bhakta Z, Leclair L, Parrot M, Young DC. Population pharmacokinetics and target attainment analysis of vancomycin after intermittent dosing in adults with cystic fibrosis. Antimicrob Agents Chemother. 2024 Jan 10; 68(1):e0099223.
-
Calado Nogueira de Moura V, Nguyen MH, Hunkins JJ, Daley CL, Khare R. In vitro susceptibility patterns for slowly growing non-tuberculous mycobacteria in the USA from 2018 to 2022. J Antimicrob Chemother. 2023 12 01; 78(12):2849-2858.
-
Kunz Coyne AJ, Alosaimy S, Lucas K, Lagnf AM, Morrisette T, Molina KC, DeKerlegand A, Schrack MR, Kang-Birken SL, Hobbs AL, Agee J, Perkins NB, Biagi M, Pierce M, Truong J, Andrade J, Bouchard J, Gore T, King MA, Pullinger BM, Claeys KC, Herbin S, Cosimi R, Tart S, Veve MP, Jones BM, Rojas LM, Feehan AK, Scipione MR, Zhao JJ, Witucki P, Rybak MJ. Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022. Microbiol Spectr. 2024 Jan 11; 12(1):e0235123.
-
Chastain DB, White BP, Tu PJ, Chan S, Jackson BT, Kubbs KA, Bandali A, McDougal S, Henao-Mart?nez AF, Cluck DB. Candidemia in Adult Patients in the ICU: A Reappraisal of Susceptibility Testing and Antifungal Therapy. Ann Pharmacother. 2024 Mar; 58(3):305-321.
-
Weig AW, O'Conner PM, Kwiecinski JM, Marciano OM, Nunag A, Gutierrez AT, Melander RJ, Horswill AR, Melander C. A structure activity relationship study of 3,4'-dimethoxyflavone for ArlRS inhibition in Staphylococcus aureus. Org Biomol Chem. 2023 04 26; 21(16):3373-3380.
-
Reichlen MJ, Born SEM, Lyons MA, Rossmassler K, Reid J, Robertson GT, Walter ND, Voskuil MI. Standardized RS Ratio Metrics To Assess Tuberculosis Antimicrobial Efficacy and Potency. Antimicrob Agents Chemother. 2023 01 24; 67(1):e0148322.
-
Torian SC, Wiktor AJ, Roper SE, Laramie KE, Miller MA, Mueller SW. Burn Injury and Augmented Renal Clearance: A Case for Optimized Piperacillin-Tazobactam Dosing. J Burn Care Res. 2023 01 05; 44(1):203-206.
-
Hunkins JJ, de-Moura VC, Eddy JJ, Daley CL, Khare R. In vitro susceptibility patterns for rapidly growing nontuberculous mycobacteria in the United States. Diagn Microbiol Infect Dis. 2023 Mar; 105(3):115882.
-
Alosaimy S, Morrisette T, Lagnf AM, Rojas LM, King MA, Pullinger BM, Hobbs ALV, Perkins NB, Veve MP, Bouchard J, Gore T, Jones B, Truong J, Andrade J, Huang G, Cosimi R, Kang-Birken SL, Molina KC, Biagi M, Pierce M, Scipione MR, Zhao JJ, Davis SL, Rybak MJ. Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii. Microbiol Spectr. 2022 10 26; 10(5):e0047922.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|